MX230696B - 5-cloro-3-(4-metansulfonilfenil)-6'-metil-[2,3]-bipiridinilo en forma cristalina pura, y procedimiento para su sintesis. - Google Patents

5-cloro-3-(4-metansulfonilfenil)-6'-metil-[2,3]-bipiridinilo en forma cristalina pura, y procedimiento para su sintesis.

Info

Publication number
MX230696B
MX230696B MXPA02011619A MX230696B MX 230696 B MX230696 B MX 230696B MX PA02011619 A MXPA02011619 A MX PA02011619A MX 230696 B MX230696 B MX 230696B
Authority
MX
Mexico
Prior art keywords
methanesulfonylphenyl
bipyridinyl
chloro
synthesis
methyl
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Ian W Davies
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX230696(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MXPA02011619A publication Critical patent/MXPA02011619A/es
Publication of MX230696B publication Critical patent/MX230696B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA02011619 2000-05-26 2001-05-22 5-cloro-3-(4-metansulfonilfenil)-6'-metil-[2,3]-bipiridinilo en forma cristalina pura, y procedimiento para su sintesis. MX230696B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20801700P 2000-05-26 2000-05-26
PCT/US2001/016566 WO2001092230A1 (en) 2000-05-26 2001-05-22 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis

Publications (2)

Publication Number Publication Date
MXPA02011619A MXPA02011619A (es) 2003-03-27
MX230696B true MX230696B (es) 2005-09-19

Family

ID=22772880

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011619 MX230696B (es) 2000-05-26 2001-05-22 5-cloro-3-(4-metansulfonilfenil)-6'-metil-[2,3]-bipiridinilo en forma cristalina pura, y procedimiento para su sintesis.

Country Status (48)

Country Link
EP (1) EP1296951B1 (cg-RX-API-DMAC7.html)
JP (2) JP3665053B2 (cg-RX-API-DMAC7.html)
KR (1) KR100757699B1 (cg-RX-API-DMAC7.html)
CN (1) CN1227233C (cg-RX-API-DMAC7.html)
AR (1) AR028577A1 (cg-RX-API-DMAC7.html)
AT (1) ATE483687T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001264804B2 (cg-RX-API-DMAC7.html)
BG (1) BG65855B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0111140B8 (cg-RX-API-DMAC7.html)
CA (1) CA2410234C (cg-RX-API-DMAC7.html)
CR (1) CR6606A (cg-RX-API-DMAC7.html)
CY (1) CY1111440T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20023888A3 (cg-RX-API-DMAC7.html)
DE (1) DE60143197D1 (cg-RX-API-DMAC7.html)
DK (1) DK1296951T3 (cg-RX-API-DMAC7.html)
EA (1) EA004809B1 (cg-RX-API-DMAC7.html)
EE (1) EE05242B1 (cg-RX-API-DMAC7.html)
EG (1) EG24189A (cg-RX-API-DMAC7.html)
ES (1) ES2351958T3 (cg-RX-API-DMAC7.html)
GC (1) GC0000362A (cg-RX-API-DMAC7.html)
GE (1) GEP20053492B (cg-RX-API-DMAC7.html)
GT (1) GT200100091A (cg-RX-API-DMAC7.html)
HN (1) HN2001000110A (cg-RX-API-DMAC7.html)
HR (1) HRP20020934B1 (cg-RX-API-DMAC7.html)
HU (1) HU228423B1 (cg-RX-API-DMAC7.html)
IL (1) IL152582A0 (cg-RX-API-DMAC7.html)
IN (2) IN2002CH02089A (cg-RX-API-DMAC7.html)
IS (1) IS2806B (cg-RX-API-DMAC7.html)
JO (1) JO2216B1 (cg-RX-API-DMAC7.html)
MA (1) MA26919A1 (cg-RX-API-DMAC7.html)
ME (1) ME00428B (cg-RX-API-DMAC7.html)
MX (1) MX230696B (cg-RX-API-DMAC7.html)
MY (1) MY123569A (cg-RX-API-DMAC7.html)
NO (1) NO324495B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ522394A (cg-RX-API-DMAC7.html)
PA (1) PA8516901A1 (cg-RX-API-DMAC7.html)
PE (1) PE20011324A1 (cg-RX-API-DMAC7.html)
PH (1) PH12001001175B1 (cg-RX-API-DMAC7.html)
PL (1) PL358153A1 (cg-RX-API-DMAC7.html)
PT (1) PT1296951E (cg-RX-API-DMAC7.html)
RS (1) RS51541B (cg-RX-API-DMAC7.html)
SI (1) SI1296951T1 (cg-RX-API-DMAC7.html)
SK (1) SK287174B6 (cg-RX-API-DMAC7.html)
SV (1) SV2002000462A (cg-RX-API-DMAC7.html)
TW (1) TWI303634B (cg-RX-API-DMAC7.html)
UA (1) UA73355C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001092230A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200209558B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019021079A1 (en) 2017-07-26 2019-01-31 Laboratorios Liomont, S.A. De C.V. PHARMACEUTICAL COMPOSITION HAVING A RELATIVE RANGE BETWEEN TRAMADOL HYDROCHLORIDE AND ETORICOXIB FOR ITS ADMINISTRATION FOR THE TREATMENT OF PAIN

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320809T1 (de) * 1999-11-29 2006-04-15 Merck Frosst Canada Inc Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PL2479166T3 (pl) 2009-02-27 2014-11-28 Cadila Healthcare Ltd Sposób otrzymywania etorykoksybu
WO2012004677A1 (en) 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
WO2013105106A1 (en) 2011-11-03 2013-07-18 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
WO2014033526A1 (en) 2012-08-27 2014-03-06 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
EP2888231B1 (en) 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN106632003B (zh) * 2015-12-31 2019-02-12 上海博志研新药物技术有限公司 一种依托考昔的制备方法
CN108069896B (zh) * 2016-11-11 2022-08-12 昆明积大制药股份有限公司 一种依托考昔晶型的制备方法
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
CN107417599B (zh) * 2017-06-21 2020-06-09 四川尚锐生物医药有限公司 一种依托考昔晶型的制备方法
CN107556231A (zh) * 2017-09-23 2018-01-09 江苏正大清江制药有限公司 一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107417600A (zh) * 2017-09-26 2017-12-01 江苏正大清江制药有限公司 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法
CN107898787B (zh) * 2017-12-15 2018-11-30 扬子江药业集团上海海尼药业有限公司 一种药物组合物及其制剂和制备方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN110143915A (zh) * 2019-06-03 2019-08-20 蚌埠学院 一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CA2260016C (en) * 1996-07-18 2004-03-09 Merck Frosst Canada Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CN1178658C (zh) * 1998-04-24 2004-12-08 麦克公司 合成环加氧酶-2抑制剂的方法
ATE320809T1 (de) * 1999-11-29 2006-04-15 Merck Frosst Canada Inc Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2, 3')bipyridinyl

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019021079A1 (en) 2017-07-26 2019-01-31 Laboratorios Liomont, S.A. De C.V. PHARMACEUTICAL COMPOSITION HAVING A RELATIVE RANGE BETWEEN TRAMADOL HYDROCHLORIDE AND ETORICOXIB FOR ITS ADMINISTRATION FOR THE TREATMENT OF PAIN

Also Published As

Publication number Publication date
ATE483687T1 (de) 2010-10-15
NZ522394A (en) 2004-05-28
CN1443168A (zh) 2003-09-17
DK1296951T3 (da) 2011-01-24
AU2001264804B2 (en) 2006-04-06
IS2806B (is) 2012-09-15
GC0000362A (en) 2007-03-31
JO2216B1 (en) 2004-10-07
MY123569A (en) 2006-05-31
EE05242B1 (et) 2009-12-15
BRPI0111140B1 (pt) 2018-03-13
YU89402A (sh) 2005-11-28
SV2002000462A (es) 2002-03-08
IS6630A (is) 2002-11-20
UA73355C2 (en) 2005-07-15
DE60143197D1 (de) 2010-11-18
PT1296951E (pt) 2010-12-07
MXPA02011619A (es) 2003-03-27
CA2410234C (en) 2008-05-13
JP4142621B2 (ja) 2008-09-03
CZ20023888A3 (cs) 2003-02-12
IL152582A0 (en) 2003-05-29
MA26919A1 (fr) 2004-12-20
CA2410234A1 (en) 2001-12-06
PA8516901A1 (es) 2002-04-25
HU228423B1 (en) 2013-03-28
ME00428B (me) 2011-10-10
JP2005047927A (ja) 2005-02-24
PE20011324A1 (es) 2002-01-28
KR20030003762A (ko) 2003-01-10
RS51541B (sr) 2011-06-30
HUP0302336A2 (hu) 2003-11-28
SK287174B6 (sk) 2010-02-08
NO20025674L (no) 2002-11-26
EP1296951B1 (en) 2010-10-06
BG107237A (bg) 2003-05-30
WO2001092230A1 (en) 2001-12-06
IN2007CH05103A (cg-RX-API-DMAC7.html) 2008-08-27
PH12001001175B1 (en) 2006-08-10
AR028577A1 (es) 2003-05-14
CR6606A (es) 2006-02-06
IN2002CH02089A (cg-RX-API-DMAC7.html) 2005-02-25
EG24189A (en) 2008-10-08
KR100757699B1 (ko) 2007-09-13
SK16702002A3 (sk) 2003-05-02
EP1296951A1 (en) 2003-04-02
JP3665053B2 (ja) 2005-06-29
BRPI0111140B8 (pt) 2021-05-25
HK1058932A1 (en) 2004-06-11
HRP20020934B1 (en) 2012-01-31
EA200201264A1 (ru) 2003-04-24
AU6480401A (en) 2001-12-11
NO20025674D0 (no) 2002-11-26
GT200100091A (es) 2001-12-28
BG65855B1 (bg) 2010-03-31
ES2351958T3 (es) 2011-02-14
PL358153A1 (en) 2004-08-09
NO324495B1 (no) 2007-10-29
EA004809B1 (ru) 2004-08-26
CY1111440T1 (el) 2015-08-05
TWI303634B (en) 2008-12-01
EE200200655A (et) 2004-08-16
BR0111140A (pt) 2005-01-11
CN1227233C (zh) 2005-11-16
JP2004501116A (ja) 2004-01-15
GEP20053492B (en) 2005-04-25
ZA200209558B (en) 2003-10-28
HRP20020934A2 (en) 2005-02-28
HN2001000110A (es) 2002-03-06
SI1296951T1 (sl) 2011-01-31

Similar Documents

Publication Publication Date Title
MX230696B (es) 5-cloro-3-(4-metansulfonilfenil)-6'-metil-[2,3]-bipiridinilo en forma cristalina pura, y procedimiento para su sintesis.
HUP0301802A3 (en) Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
HUP0303109A3 (en) Indolin-2-one derivatives, process for producing them and pharmaceutical compositions containing them
HUP0300196A3 (en) 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses
HUP0000748A3 (en) 4-phenyl-piridine derivatives, process for producing them and pharmaceutical compositions containing them
HUP0301651A2 (en) Indolylmaleimide derivatives, pharmaceutical compositions containing them, process for producing them and their use
AU6198700A (en) Process for producing phenyl-alkanes compositions produced therefrom, and uses thereof
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
AU2001292124A1 (en) Package, in particular for tobacco products
HUP0202736A3 (en) Substituted aromatic-ring compounds, process for producing the same, and pharmaceutical compositions containing them and use thereof
HUP0105479A3 (en) Betha-alanine derivatives, process for producing them and pharmaceutical compositions containing them
ZA200500065B (en) Crystalline 2,5,-dione-3-(1-methyl-1H-indol-3-yl)-Ä1-(pyridin-2-ylmethyl)piperidin-4-ylÜ-1H-indol-3-ylÜ-1H-pyrrole mono-hydrochloride
AU5067899A (en) Process for preparing alpha-(1,4) linked oligosaccharide
EP1395562A4 (en) 5-CHLORO-3- (4-METHANSULFONYL PHENYL) -6 - METHYLC2,3-] BIPYRIDINYL IN PURE CRYSTALLINE FORM AND SYNTHESIS METHOD
AU2001271058A1 (en) Method for producing 1-substituted-1,2,3-triazole derivative
HUP0201916A3 (en) Ethanesulfonyl-piperidine derivatives, process for producing them and pharmaceutical compositions containing them
AU2002223766A1 (en) Single crystals, method for making single crystals by growth in solution and uses
MXPA03002926A (es) Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.
MXPA03004849A (es) Coniosetina y sus derivados, metodo para producirla y su uso.
HUP9900263A3 (en) 11-acetyl-12,13-dioxabicyclo[8.2.1.]tridecenon derivatives, process for producing them and pharmaceutical compositions containing them
IL146573A0 (en) Method for producing 2,2,4,4-tetra-substituted 1,3,5-cyclohexanetriones
AU7560200A (en) Fat originating in cupuassu seed, process for producing the same and use thereof
MXPA03004679A (es) Procedimiento para preparar derivados de distamicina.
AU2002228593A1 (en) Process for preparing alpha-(3-arylthio)-acetophenones
MXPA03008636A (es) Derivados de isoquinuclidina, metodo para fabricar los mismos y agentes terapeuticos que contienen estos compuestos.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status
GB Transfer or rights
HC Change of company name or juridical status
GD Licence granted